Your browser doesn't support javascript.
loading
Oncogenic HER2 fusions in gastric cancer.
Yu, De-Hua; Tang, Lili; Dong, Hua; Dong, Zhengwei; Zhang, Lianhai; Fu, Jiangang; Su, Xinying; Zhang, Tianwei; Fu, Haihua; Han, Lu; Xie, Liang; Chen, Hao; Qian, Ziliang; Zhu, Guanshan; Wang, Jia; Ye, Qingqing; Zhang, Jingchuan; Yin, Xiaolu; Zhang, Xiaolin; Ji, Jiafu; Ji, Qunsheng.
Afiliação
  • Yu DH; Innovation Center China, Asia & Emerging Market iMed, AstraZeneca Innovation Medicines and Early Development, 199 Liangjing Road, Zhangjiang Hi-Tech Park, Shanghai, 201203, China. yudehua@yahoo.com.
  • Tang L; Innovation Center China, Asia & Emerging Market iMed, AstraZeneca Innovation Medicines and Early Development, 199 Liangjing Road, Zhangjiang Hi-Tech Park, Shanghai, 201203, China. lily.tang@astrazeneca.com.
  • Dong H; Innovation Center China, Asia & Emerging Market iMed, AstraZeneca Innovation Medicines and Early Development, 199 Liangjing Road, Zhangjiang Hi-Tech Park, Shanghai, 201203, China. hua.dong@astrazeneca.com.
  • Dong Z; Innovation Center China, Asia & Emerging Market iMed, AstraZeneca Innovation Medicines and Early Development, 199 Liangjing Road, Zhangjiang Hi-Tech Park, Shanghai, 201203, China. harvey.dong@astrazeneca.com.
  • Zhang L; Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Surgery, Peking University Cancer Hospital and Institute, Beijing, China. zlhzlh@hotmail.com.
  • Fu J; Innovation Center China, Asia & Emerging Market iMed, AstraZeneca Innovation Medicines and Early Development, 199 Liangjing Road, Zhangjiang Hi-Tech Park, Shanghai, 201203, China. jiangang.fu@astrazeneca.com.
  • Su X; Innovation Center China, Asia & Emerging Market iMed, AstraZeneca Innovation Medicines and Early Development, 199 Liangjing Road, Zhangjiang Hi-Tech Park, Shanghai, 201203, China. xinying.su@astrazeneca.com.
  • Zhang T; Innovation Center China, Asia & Emerging Market iMed, AstraZeneca Innovation Medicines and Early Development, 199 Liangjing Road, Zhangjiang Hi-Tech Park, Shanghai, 201203, China. tianwei.zhang@astrazeneca.com.
  • Fu H; Innovation Center China, Asia & Emerging Market iMed, AstraZeneca Innovation Medicines and Early Development, 199 Liangjing Road, Zhangjiang Hi-Tech Park, Shanghai, 201203, China. haihua.fu@astrazeneca.com.
  • Han L; Innovation Center China, Asia & Emerging Market iMed, AstraZeneca Innovation Medicines and Early Development, 199 Liangjing Road, Zhangjiang Hi-Tech Park, Shanghai, 201203, China. luna.han@astrazeneca.com.
  • Xie L; Innovation Center China, Asia & Emerging Market iMed, AstraZeneca Innovation Medicines and Early Development, 199 Liangjing Road, Zhangjiang Hi-Tech Park, Shanghai, 201203, China. xieliang_02@yahoo.com.
  • Chen H; Department of General Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. hyschen@163.com.
  • Qian Z; Innovation Center China, Asia & Emerging Market iMed, AstraZeneca Innovation Medicines and Early Development, 199 Liangjing Road, Zhangjiang Hi-Tech Park, Shanghai, 201203, China. zl_qian@aliyun.com.
  • Zhu G; Innovation Center China, Asia & Emerging Market iMed, AstraZeneca Innovation Medicines and Early Development, 199 Liangjing Road, Zhangjiang Hi-Tech Park, Shanghai, 201203, China. guanshan_zhu@hotmail.com.
  • Wang J; Innovation Center China, Asia & Emerging Market iMed, AstraZeneca Innovation Medicines and Early Development, 199 Liangjing Road, Zhangjiang Hi-Tech Park, Shanghai, 201203, China. jia.wang@astrazeneca.com.
  • Ye Q; Innovation Center China, Asia & Emerging Market iMed, AstraZeneca Innovation Medicines and Early Development, 199 Liangjing Road, Zhangjiang Hi-Tech Park, Shanghai, 201203, China. yeqingqing616@163.com.
  • Zhang J; Innovation Center China, Asia & Emerging Market iMed, AstraZeneca Innovation Medicines and Early Development, 199 Liangjing Road, Zhangjiang Hi-Tech Park, Shanghai, 201203, China. jingchuanzhang@yahoo.com.
  • Yin X; Innovation Center China, Asia & Emerging Market iMed, AstraZeneca Innovation Medicines and Early Development, 199 Liangjing Road, Zhangjiang Hi-Tech Park, Shanghai, 201203, China. lucy.yin@astrazeneca.com.
  • Zhang X; Innovation Center China, Asia & Emerging Market iMed, AstraZeneca Innovation Medicines and Early Development, 199 Liangjing Road, Zhangjiang Hi-Tech Park, Shanghai, 201203, China. xiaolin.zhang@astrazeneca.com.
  • Ji J; Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Surgery, Peking University Cancer Hospital and Institute, Beijing, China. jiafuj@hotmail.com.
  • Ji Q; Innovation Center China, Asia & Emerging Market iMed, AstraZeneca Innovation Medicines and Early Development, 199 Liangjing Road, Zhangjiang Hi-Tech Park, Shanghai, 201203, China. qsji18@yahoo.com.
J Transl Med ; 13: 116, 2015 Apr 11.
Article em En | MEDLINE | ID: mdl-25889497
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oncogenes / Neoplasias Gástricas / Genes erbB-2 Limite: Animals / Humans Idioma: En Revista: J Transl Med Ano de publicação: 2015 Tipo de documento: Article País de afiliação: China
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oncogenes / Neoplasias Gástricas / Genes erbB-2 Limite: Animals / Humans Idioma: En Revista: J Transl Med Ano de publicação: 2015 Tipo de documento: Article País de afiliação: China